Fujita Innovation Capital
Overview
Fujita Innovation Capital is the corporate venture capital arm of Fujita Gakuen Educational, established to invest in and support startups in the medical, bio, and healthcare sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cardio Intelligence Inc. | Nov 2023 | Series B | Co-investor |
| Metagen Therapeutics, Inc. | Feb 2026 | Series B | Co-investor |
| B dot Medical Inc. | Oct 2025 | Series B2 | Co-investor |
| United Immunity, Co., Ltd. | Sep 2026 | VC Round | Co-investor |
| Vitaars Inc. | Jun 2023 | Series C | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Fujita Innovation Capital based?
Fujita Innovation Capital is headquartered in Toyoake, Japan.
When was Fujita Innovation Capital founded?
Fujita Innovation Capital was founded in 2019.
How many portfolio companies does Fujita Innovation Capital have?
Fujita Innovation Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Fujita Innovation Capital's portfolio?
Portfolio companies visible on Caplight include Cardio Intelligence Inc., Metagen Therapeutics, Inc., B dot Medical Inc., United Immunity, Co., Ltd., Vitaars Inc..
What was Fujita Innovation Capital's most recent investment shown here?
Fujita Innovation Capital's most recent investment in this portfolio sample was in United Immunity, Co., Ltd. in 2026.
What sectors does Fujita Innovation Capital focus on?
Fujita Innovation Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, Enterprise Software.
What company stages does Fujita Innovation Capital focus on?
Fujita Innovation Capital typically invests at the Mid stage.
What is Fujita Innovation Capital's AUM?
Fujita Innovation Capital's assets under management are estimated between $12.7M and $25.5M.